Company Profile:

ChemPartner PharmaTech Co., Ltd. (Stock Abbreviation: ChemPartner; Stock Code: 300149) is a biotechnology-driven company focused on pharmaceutical research and development outsourcing, manufacturing services, and microbiome-based healthcare.

ChemPartner provides integrated, end-to-end solutions for global mid- to large-sized pharmaceutical companies, biotechnology firms, and academic research institutions. Its services span the full value chain of both biologics and small-molecule drugs—from early-stage discovery through development to commercial-scale manufacturing. In parallel, the Company advances standardized and precision-driven microbiome healthcare solutions, supporting human microbiome health management. ChemPartner is committed to becoming a leading global CRO & CDMO partner and a comprehensive, lifecycle-based solutions provider for pharmaceutical innovation.

The Company operates five nationally recognized high-tech enterprises and has built a large, industry-leading scientific team of more than 2,000 R&D professionals. Headquartered in Shanghai, China, ChemPartner has established research institutes, laboratories, manufacturing facilities, and operational entities across the United States, Denmark, Hong Kong, Shanghai, Guangzhou, Chengdu, and Jiangmen, with a global sales and service network spanning five continents.

Guided by its philosophy of “Science-Driven, Technology-Led Innovation” and its vision to “Become a Global Leader in Pharmaceutical and Healthcare Innovation Services,” ChemPartner is dedicated to advancing the transformation and upgrading of China’s pharmaceutical industry, while continuously empowering global healthcare innovation and serving as a sustained driving force for the development of innovative medicines worldwide.

Chairman: WOO SWEE LIAN
Director: Fan Shixin, Chen Wanglong
Independent Directors: Guo Zhicheng, Wang Xianzhong, Zhang Xuemei
Chief Executive Officer (CEO): WOO SWEE LIAN
Company Secretary: WOO SWEE LIAN